Sandoz's Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia
Shots:
- The approval is based on non-inferiority data with the reference biologic (Neulasta) showing biosimilarity in terms of safety- efficacy and quality
- Ziextenzo is a long-lasting form of filgrastim indicated to reduce duration of neutropenia and occurrence of febrile neutropenia in adult treated with cytotoxic (anti-cancer) CT
- Sandoz has received eight biosimilars approval worldwide- with five in the last 18 months
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
